(Corrects ninth bullet to say "An Abu Dhabi investment company" not "Waleed al-Mokarrab al-Muhairi" owns 45% of Ellipses in November 18 story)

Nov 18 (Reuters) - British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a London listing through a deal with special purpose acquisition company Wolfram Resources. 

• The company is targeting a valuation of between £450 million and £500 million ($594 million-$660 million), the Times reported on Sunday

• Established in 2017, Ellipses Pharma's pipeline includes trials for drugs to treat non-small cell lung cancer and breast cancer

• The London listing would follow a reverse takeover by shell company Wolfram Resources

• Terms of the deal are yet to be agreed and have not been disclosed

• The floatation will provide a boost to the UK stock market, which has seen an exodus from companies eyeing higher valuations in markets like the United States

• Ellipses Pharma is targeting completing the transaction by early 2027

• It expects an equity fundraise in conjunction with the deal

• Listing through a reverse takeover process will enable the company to raise additional capital from public company investors, founder and chair Chris Evans said

• An Abu Dhabi investment company owns about 45% of Ellipses, the Times report said

• The report also named celebrity investors such as composer Andrew Lloyd Webber, Rolling Stones guitarist Ronnie Wood and comedian Jimmy Carr

• The company did not immediately comment on valuation and investors

(Reporting by Simone Lobo in Bengaluru; Editing by Nivedita Bhattacharjee)

Find it fast

Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education